J Breast Cancer.  2021 Dec;24(6):561-568. 10.4048/jbc.2021.24.e54.

Prognostic Factors in Male Breast Cancer: A Retrospective Nationwide Study in South Korea by the Study of SMARTSHIP Group

  • 1Department of Breast Surgery, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea
  • 2Department of Surgery, National Health Insurance Service Ilsan Hospital, Goyang, Korea
  • 3Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  • 4Department of Biostatistics, Korea University, Seoul, Korea
  • 5Department of Surgery, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
  • 6Department of Surgery, Asan Medical Center, Seoul, Korea
  • 7Department of Surgery, Chonbuk National University Hospital, Jeonju, Korea
  • 8Department of Surgery, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea
  • 9Department of Surgery, Soonchunhyang University Seoul Hospital, Seoul, Korea


This study evaluated the incidence, the survival outcomes and its prognostic factors for male breast cancer (MBC) in Korea. Using the National Health Insurance Service database of Korea, we identified MBC patients who had the new claim code of C50. Medical records including type of surgeries and radiotherapy within one year of the first claim and death records were reviewed. Between 2005 and 2016, 838 newly diagnosed MBC patients were included (median follow-up, 1,769 days). The 70–74-year age group had the highest incidence of MBC. The 5-year survival rate was 73.7%. Age > 65 years, low income, no surgical intervention, no tamoxifen use, and > 2 comorbidities correlated with a worse outcome. MBC incidence has increased over time, and its peak is noted at age > 70 years. Age > 65 years, > 2 comorbidities, no surgical intervention, and no tamoxifen use correlate to poor prognosis.


Breast Neoplasms; Male; Incidence; Prognosis; Therapeutics
Full Text Links
  • JBC
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr